Tue, Jan 27, 2015, 1:30 AM EST - U.S. Markets open in 8 hrs.

Recent

% | $
Quotes you view appear here for quick access.

Osiris Therapeutics, Inc. Message Board

  • scistats scistats Jul 17, 2013 2:30 AM Flag

    Yet another new Prochymal GvHD patent out 7/16/13.

    By golly, I think Osiris is taking this GvHD seriously!!!

    Mesenchymal stem cells expressing TNF-alpha receptors
    United States Patent 8486695

    Abstract:
    Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Sci guy, WHAT would I do without YOU.

      Thank you for all you DO.

      Sentiment: Strong Buy

      • 1 Reply to ativaloc
      • Things are looking good Ativaloc! We are in the Swissmedic sweet spot near Prochymal approval, and this new patent tells us there is definitely a Prochymal 2.0. With Sales Team Grafix moving in hot pursuit of Pete and his EpiFix, we could easily see a run at $20 PPS. Petit and Osiris will battle it out from here on, but I think California is Grafix country, and its Randy's to lose. New products on the way. Pressure on Grafix in Crohn's but looks viable otherwise with AMI being the wild card. Randy needs to keep putting the spurs to biosurgery and loosen up the reigns. Let it run with the new products out as soon as possible. If a partnership can be averted, Osiris could be the next Genzyme or Genentech. Stem cell heart stents may be next. Look out! Cheers.

        Sentiment: Strong Buy

 
OSIR
16.90+0.01(+0.06%)Jan 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.